JP2019516410A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019516410A5 JP2019516410A5 JP2019513483A JP2019513483A JP2019516410A5 JP 2019516410 A5 JP2019516410 A5 JP 2019516410A5 JP 2019513483 A JP2019513483 A JP 2019513483A JP 2019513483 A JP2019513483 A JP 2019513483A JP 2019516410 A5 JP2019516410 A5 JP 2019516410A5
- Authority
- JP
- Japan
- Prior art keywords
- segment
- pitindevirus
- pitin
- utr
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002245 particle Substances 0.000 claims description 118
- 239000000427 antigen Substances 0.000 claims description 59
- 102000036639 antigens Human genes 0.000 claims description 59
- 108091007433 antigens Proteins 0.000 claims description 59
- 241000700605 Viruses Species 0.000 claims description 48
- 108020005345 3' Untranslated Regions Proteins 0.000 claims description 40
- 108020003589 5' Untranslated Regions Proteins 0.000 claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 206010028980 Neoplasm Diseases 0.000 claims description 30
- 238000000034 method Methods 0.000 claims description 29
- 101001065501 Escherichia phage MS2 Lysis protein Proteins 0.000 claims description 21
- 108700026244 Open Reading Frames Proteins 0.000 claims description 21
- 208000015181 infectious disease Diseases 0.000 claims description 18
- 230000002458 infectious effect Effects 0.000 claims description 18
- 102000004169 proteins and genes Human genes 0.000 claims description 18
- 239000002299 complementary DNA Substances 0.000 claims description 14
- 230000003612 virological effect Effects 0.000 claims description 10
- 230000035897 transcription Effects 0.000 claims description 9
- 238000013518 transcription Methods 0.000 claims description 9
- 241000701022 Cytomegalovirus Species 0.000 claims description 6
- 241000711549 Hepacivirus C Species 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 6
- 102000017143 RNA Polymerase I Human genes 0.000 claims description 6
- 108010013845 RNA Polymerase I Proteins 0.000 claims description 6
- 102000009572 RNA Polymerase II Human genes 0.000 claims description 6
- 108010009460 RNA Polymerase II Proteins 0.000 claims description 6
- 239000013566 allergen Substances 0.000 claims description 6
- 230000015572 biosynthetic process Effects 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 5
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims description 5
- 230000002457 bidirectional effect Effects 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 5
- 102000034287 fluorescent proteins Human genes 0.000 claims description 5
- 108020004635 Complementary DNA Proteins 0.000 claims description 4
- 108020004414 DNA Proteins 0.000 claims description 4
- 108010086140 Interferon alpha-beta Receptor Proteins 0.000 claims description 4
- 102000007438 Interferon alpha-beta Receptor Human genes 0.000 claims description 4
- 241000699670 Mus sp. Species 0.000 claims description 4
- 208000037581 Persistent Infection Diseases 0.000 claims description 4
- 230000000694 effects Effects 0.000 claims description 4
- 239000013604 expression vector Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 230000002238 attenuated effect Effects 0.000 claims description 3
- 102000003886 Glycoproteins Human genes 0.000 claims description 2
- 108090000288 Glycoproteins Proteins 0.000 claims description 2
- 108060003393 Granulin Proteins 0.000 claims description 2
- 108091026898 Leader sequence (mRNA) Proteins 0.000 claims description 2
- 108060004795 Methyltransferase Proteins 0.000 claims description 2
- 102000007999 Nuclear Proteins Human genes 0.000 claims description 2
- 108010089610 Nuclear Proteins Proteins 0.000 claims description 2
- 239000013612 plasmid Substances 0.000 claims description 2
- 102100039793 E3 ubiquitin-protein ligase RAG1 Human genes 0.000 claims 4
- 101000744443 Homo sapiens E3 ubiquitin-protein ligase RAG1 Proteins 0.000 claims 4
- 241000700721 Hepatitis B virus Species 0.000 claims 3
- 241001631646 Papillomaviridae Species 0.000 claims 3
- 108010054267 Interferon Receptors Proteins 0.000 claims 2
- 102000001617 Interferon Receptors Human genes 0.000 claims 2
- 230000001629 suppression Effects 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 210000002845 virion Anatomy 0.000 description 4
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- 102000001183 RAG-1 Human genes 0.000 description 2
- 108060006897 RAG1 Proteins 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 108010054624 red fluorescent protein Proteins 0.000 description 2
- 108010077753 type II interferon receptor Proteins 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000010415 tropism Effects 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022161464A JP7547433B2 (ja) | 2016-05-18 | 2022-10-06 | ワクチンベクターとしての三セグメントピチンデウイルス |
| JP2024146333A JP2024170461A (ja) | 2016-05-18 | 2024-08-28 | ワクチンベクターとしての三セグメントピチンデウイルス |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662338400P | 2016-05-18 | 2016-05-18 | |
| US62/338,400 | 2016-05-18 | ||
| PCT/EP2017/061865 WO2017198726A1 (en) | 2016-05-18 | 2017-05-17 | Tri-segmented pichinde viruses as vaccine vectors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022161464A Division JP7547433B2 (ja) | 2016-05-18 | 2022-10-06 | ワクチンベクターとしての三セグメントピチンデウイルス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019516410A JP2019516410A (ja) | 2019-06-20 |
| JP2019516410A5 true JP2019516410A5 (cg-RX-API-DMAC7.html) | 2020-07-02 |
| JP7254018B2 JP7254018B2 (ja) | 2023-04-07 |
Family
ID=58800799
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019513483A Active JP7254018B2 (ja) | 2016-05-18 | 2017-05-17 | ワクチンベクターとしての三セグメントピチンデウイルス |
| JP2022161464A Active JP7547433B2 (ja) | 2016-05-18 | 2022-10-06 | ワクチンベクターとしての三セグメントピチンデウイルス |
| JP2024146333A Pending JP2024170461A (ja) | 2016-05-18 | 2024-08-28 | ワクチンベクターとしての三セグメントピチンデウイルス |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022161464A Active JP7547433B2 (ja) | 2016-05-18 | 2022-10-06 | ワクチンベクターとしての三セグメントピチンデウイルス |
| JP2024146333A Pending JP2024170461A (ja) | 2016-05-18 | 2024-08-28 | ワクチンベクターとしての三セグメントピチンデウイルス |
Country Status (14)
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI2604695T1 (sl) | 2007-12-27 | 2023-03-31 | Universitaet Zuerich Prorektorat Forschung | Replikacijsko defektni arenavirusni vektorji |
| ES2868427T3 (es) | 2013-12-03 | 2021-10-21 | Hookipa Biotech Ag | Vacunas contra el CMV |
| CA2967720C (en) | 2014-11-13 | 2024-01-02 | Universite De Geneve | Tri-segmented arenaviruses as vaccine vectors |
| EP3307308A2 (en) | 2015-06-10 | 2018-04-18 | Hookipa Biotech AG | Hpv vaccines |
| HRP20221474T1 (hr) | 2015-11-04 | 2023-01-06 | Hookipa Biotech Gmbh | Cjepiva protiv virusa hepatitisa b |
| SI3373959T1 (sl) | 2015-11-12 | 2022-11-30 | Hookipa Biotech Gmbh | Arenavirusni delci kot cepiva proti raku |
| AU2018247958A1 (en) * | 2017-04-07 | 2019-10-10 | Hookipa Biotech Gmbh | Arenavirus particles to treat solid tumors |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| KR102776925B1 (ko) | 2019-06-25 | 2025-03-11 | 길리애드 사이언시즈, 인코포레이티드 | Flt3l-fc 융합 단백질 및 사용 방법 |
| JP7454645B2 (ja) | 2019-07-16 | 2024-03-22 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン並びにその作製方法及び使用方法 |
| IL315295A (en) | 2019-09-30 | 2024-10-01 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| WO2021089853A1 (en) | 2019-11-07 | 2021-05-14 | Universität Basel | Arenaviruses as vectors |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| PH12022551441A1 (en) | 2019-12-24 | 2023-11-20 | Carna Biosciences Inc | Diacylglycerol kinase modulating compounds |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| EP4157342A1 (en) | 2020-05-29 | 2023-04-05 | Hookipa Biotech GmbH | Cancer treatment strategies using arenavirus vectors |
| JP7693813B2 (ja) | 2021-01-14 | 2025-06-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｉｖワクチン及び使用方法 |
| JP2024512566A (ja) | 2021-03-23 | 2024-03-19 | ホオキパ バイオテック ジーエムビーエイチ | 前立腺癌の治療に使用されるアレナウイルス |
| TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
| EP4337320A1 (en) | 2021-05-13 | 2024-03-20 | Hookipa Biotech GmbH | Arenaviruses as vectors |
| WO2022269362A2 (en) * | 2021-06-21 | 2022-12-29 | Vaxxinova International B.V. | Veterinary viral vector |
| EP4359413A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| CN117377671A (zh) | 2021-06-23 | 2024-01-09 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
| EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| KR20240109607A (ko) | 2021-11-08 | 2024-07-11 | 후키파 바이오테크 게엠베하 | 암 면역요법으로서 변이 kras, 돌연변이된 암 유발 유전자, 또는 종양 연관 항원을 발현하는 변형된 아레나바이러스 입자 |
| US20250057931A1 (en) | 2022-02-08 | 2025-02-20 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| CA3259040A1 (en) | 2022-07-12 | 2024-01-18 | Gilead Sciences, Inc. | HIV Immunogenic Polypeptides and Vaccines and Their Uses |
| WO2025191169A1 (en) | 2024-03-15 | 2025-09-18 | Hookipa Biotech Gmbh | Modified arenavirus particles expressing cancer testis antigens as cancer immunotherapies |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240243A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with bulevirtide and an inhibitory nucleic acid targeting hepatitis b virus |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| ES2536426T3 (es) | 2006-03-23 | 2015-05-25 | Novartis Ag | Compuestos de imidazoquinoxalina como inmunomoduladores |
| US8063063B2 (en) | 2006-03-23 | 2011-11-22 | Novartis Ag | Immunopotentiating compounds |
| SI2604695T1 (sl) * | 2007-12-27 | 2023-03-31 | Universitaet Zuerich Prorektorat Forschung | Replikacijsko defektni arenavirusni vektorji |
| US9809801B2 (en) * | 2013-03-15 | 2017-11-07 | Université De Genève | Anti-mycobacterial vaccines |
| CN103224999B (zh) * | 2013-04-25 | 2015-11-18 | 中华人民共和国大榭出入境检验检疫局 | 检测沙粒病毒科病毒的简并引物及rt-pcr检测方法 |
| CN107109371A (zh) * | 2014-09-22 | 2017-08-29 | 明尼苏达大学评议会 | 皮钦德病毒反向遗传学系统及其使用方法 |
-
2017
- 2017-05-17 KR KR1020247018106A patent/KR20240095333A/ko active Pending
- 2017-05-17 NZ NZ748120A patent/NZ748120A/en unknown
- 2017-05-17 WO PCT/EP2017/061865 patent/WO2017198726A1/en not_active Ceased
- 2017-05-17 NZ NZ788311A patent/NZ788311A/en unknown
- 2017-05-17 CA CA3023599A patent/CA3023599A1/en active Pending
- 2017-05-17 AU AU2017266738A patent/AU2017266738B2/en active Active
- 2017-05-17 EA EA201892648A patent/EA201892648A1/ru unknown
- 2017-05-17 IL IL314272A patent/IL314272A/en unknown
- 2017-05-17 JP JP2019513483A patent/JP7254018B2/ja active Active
- 2017-05-17 KR KR1020187036105A patent/KR102671785B1/ko active Active
- 2017-05-17 SG SG11201810048VA patent/SG11201810048VA/en unknown
- 2017-05-17 US US16/302,086 patent/US20190135875A1/en not_active Abandoned
- 2017-05-17 CN CN201780044797.7A patent/CN109804074B/zh active Active
- 2017-05-17 BR BR112018073794-1A patent/BR112018073794A2/pt active Search and Examination
- 2017-05-17 EP EP17726575.8A patent/EP3458593A1/en active Pending
- 2017-05-17 MX MX2018013956A patent/MX2018013956A/es unknown
- 2017-05-17 IL IL262963A patent/IL262963B2/en unknown
- 2017-05-17 CN CN202311410316.3A patent/CN117486979A/zh active Pending
-
2018
- 2018-11-14 MX MX2024005757A patent/MX2024005757A/es unknown
-
2022
- 2022-05-23 US US17/751,319 patent/US20220289797A1/en active Pending
- 2022-10-06 JP JP2022161464A patent/JP7547433B2/ja active Active
-
2023
- 2023-12-18 AU AU2023285703A patent/AU2023285703A1/en active Pending
-
2024
- 2024-08-28 JP JP2024146333A patent/JP2024170461A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019516410A5 (cg-RX-API-DMAC7.html) | ||
| JP2023012463A5 (cg-RX-API-DMAC7.html) | ||
| JP2017535267A5 (cg-RX-API-DMAC7.html) | ||
| Afkhami et al. | Methods and clinical development of adenovirus-vectored vaccines against mucosal pathogens | |
| Lasaro et al. | New insights on adenovirus as vaccine vectors | |
| Tatsis et al. | Adenoviruses as vaccine vectors | |
| Sun et al. | The status and prospects of Epstein–Barr virus prophylactic vaccine development | |
| JP2021182922A5 (cg-RX-API-DMAC7.html) | ||
| JP2021061848A5 (cg-RX-API-DMAC7.html) | ||
| WO2021164097A1 (zh) | 用于预防新型冠状病毒的生物制品 | |
| JP2018536433A5 (cg-RX-API-DMAC7.html) | ||
| JP2018518172A5 (cg-RX-API-DMAC7.html) | ||
| FI3371316T3 (fi) | Rokotteita hepatiitti b -virusta vastaan | |
| JP2012507270A5 (cg-RX-API-DMAC7.html) | ||
| CN105861558A (zh) | 一种痘苗病毒穿梭载体及其制备方法和应用 | |
| Abdelaziz et al. | Development of a human cytomegalovirus (HCMV)-based therapeutic cancer vaccine uncovers a previously unsuspected viral block of MHC class I antigen presentation | |
| CN111218477B (zh) | 靶向感染哺乳动物细胞的禽4型腺病毒载体及其应用 | |
| CN101160055A (zh) | 慢病毒载体及其用途 | |
| JP5969044B2 (ja) | アデノウイルス生産新規細胞株及びその用途 | |
| CN114317606A (zh) | 靶向人nk细胞的腺病毒载体及其应用 | |
| CN103045544B (zh) | 预防西尼罗河病毒的重组假型杆状病毒Bac-G-prM/E及疫苗与应用 | |
| CN116855547A (zh) | 基于hsv-1的疫苗和融瘤病毒载体的构建 | |
| Lv et al. | Efficient gene transfer into T lymphocytes by fiber-modified human adenovirus 5 | |
| Krauzewicz et al. | Polyoma and papilloma virus vectors for cancer gene therapy | |
| CN103403159A (zh) | 用于基因导入的病毒载体的制造方法 |